Bioinvent

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generatingnew drug candidates to fuel the Company’s own broad clinical development pipeline or for additional licensing and partnering.

Currently, the company has five clinical programs for hematological cancer and solid tumor treatment. Furthermore, the company has a fully integrated, proprietary, state-of-the art manufacturing facility unit. Martin Welschof has been CEO since 2018.

The company is a partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program, an initiative that develops blood cancer treatment.

BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generatingnew drug candidates to fuel the Company’s own broad clinical development pipeline or for additional licensing and partnering.

Currently, the company has five clinical programs for hematological cancer and solid tumor treatment. Furthermore, the company has a fully integrated, proprietary, state-of-the art manufacturing facility unit. Martin Welschof has been CEO since 2018.

The company is a partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program, an initiative that develops blood cancer treatment.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1185446604 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

8 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.